Fungal infections have become increasingly prevalent over the past decade. Amphotericin B deoxycholate (AmBd) (Fungizone) has been the treatment of choice despite its association with significant high adverse effects, and notably severe high nephrotoxicity. However, liposomal ampotericin B (L-AmB) (AmBisome) has now become the first-line treatment due to its lower nephrotoxicity but without any loss of clinical efficacy. As illustrated in published reports, a higher dose of L-AmB may be prescribed in the case of unresponsiveness to treatment at normal dosage levels. Based on existing evidence from animal models of invasive fungal infections and the earlyclinical experience, L-AmB used athigher doses for invasive fungal infections is a new treatment option.